Ideaya Biosciences, Inc.'s stock faces pressure from macroeconomic shifts and FDA policies, but remains a buy for savvy ...

AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025AVA6103 IND-enabling studies underway with a Phase 1 trial ...

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 195+ companies and ...

MacroGenics, Inc.’s MGNX share price has dipped by 14.19%, which has investors questioning if this is right time to buy.

Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...

It is one of two novel antibiotics that promise to provide much-needed new options for people with hard-to-treat gonorrhoea, along with Innoviva’s bacterial type II topoisomerase inhibitor ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024. Financial ...

Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period. The S&P 500 dropped nearly 3% for the week, with losses in three of the ...

Both ADCs use a proprietary topoisomerase inhibitor developed by Hansoh as a cell-killing payload. Reduction in force (RIF) job losses have started in earnest at US federal agencies, including the ...

previously treated with topoisomerase-1 inhibitor (topo-1) ADCs; confirmed responses observed across all enrolled tumor types- First expansion cohort initiated in patients with TNBC previously ...

BEIJING, March 27, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual ...